Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127086521 | 12708652 | 1 | I | 20160620 | 20160829 | 20160901 | 20160901 | EXP | PHHY2016CN119623 | NOVARTIS | 55.53 | YR | M | Y | 75.00000 | KG | 20160901 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127086521 | 12708652 | 1 | PS | LESCOL | FLUVASTATIN SODIUM | 1 | Oral | 40 MG, QD | 1960 | MG | Y | X1464 | 20261 | 40 | MG | CAPSULE | QD | ||
| 127086521 | 12708652 | 2 | SS | POLYENE PHOSPHATIDYLCHOLINE | PHOSPHOLIPID | 1 | Oral | 0.46 G, TID | 23 | G | Y | K1602261 | 0 | .46 | G | CAPSULE | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127086521 | 12708652 | 1 | Blood cholesterol abnormal |
| 127086521 | 12708652 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127086521 | 12708652 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127086521 | 12708652 | Hepatic function abnormal |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127086521 | 12708652 | 1 | 20160503 | 20160620 | 0 | |
| 127086521 | 12708652 | 2 | 20160604 | 20160620 | 0 |